12 Clinical Trials Sponsored by “Atara Biotherapeutics”, Page 1 of 2

1 2

Hide Studies Not Open or Pending

1

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Condition(s):Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements; Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma; LBCL With IRF4 Rearrangement; High-grade B-cell Lymphoma With 11q Aberration; Epstein-Barr Virus-Positive DLBCL; DLBCL Associated With Chronic Inflammation; Fibrin-associated LBCL; Primary Cutaneous DLBCL, Leg Type; Intravascular LBCL; Primary Mediastinal LBCL; High-grade B-cell Lymphoma; DLBCL Arising From Transformed Indolent Lymphoma; Mediastinal Gray Zone Lymphoma; FL Grade 3B; MCLLast Updated:February 13, 2024Recruiting

2

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Condition(s):Epstein-Barr Virus (EBV)-Associated Diseases; EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD); EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD); EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD); EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders; Allogeneic Hematopoietic Cell Transplant; Stem Cell Transplant Complications; EBV+ Sarcomas; LeiomyosarcomaLast Updated:October 24, 2023Recruiting

4

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Condition(s):Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders; Allogeneic Hematopoietic Cell Transplant; Stem Cell Transplant ComplicationsLast Updated:June 24, 2022Recruiting

7

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Condition(s):Epstein-Barr Virus (EBV) Infections; Lymphoproliferative Disorders; EBV+ Associated Lymphoma; EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Epstein-Barr Viremia; Lymphoma, AIDS-related; Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID); Leiomyosarcoma (LMS); Nasopharyngeal Carcinoma (NPC); Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID); Solid Organ Transplant Complications; Stem Cell Transplant ComplicationsLast Updated:June 15, 2023No longer available

1 2

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.